Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

Table 1 Influence of the 21-gene assay on adjuvant chemotherapy recommendations

Patient population*	Patients recommended by physicians to adjuvant chemotherapy, n (%)
Patient population*	Prior to assay	After assay	Change
All	48 (46.2)	28 (26.9)	−20 (−19.2)
Low-risk	16 (32.0)	0 (0.0)	−16 (−32.0)
Intermediate-risk	18 (48.6)	11 (29.7)	−7 (−18.9)
High-risk	14 (82.4)	17 (100.0)	3 (17.6)

*Risk group determined by the 21-gene assay. Risk groups: zero to 17 is low-risk, 18 to 30 is intermediate-risk, greater than 30 is high-risk.
Source: Yamauchi et al. Clin Breast Cancer 2013 [18].

ISSN: 1472-6963